Intensity Therapeutics INTS
NASDAQ INTS
$3.42 -0.23 (-6.28%)
As of: Sep 29, 2026 · 3:55 PM EDT

Intensity Therapeutics (INTS) Depreciation & Amortization (CF) (2022 - 2023)

Updated

Intensity Therapeutics (INTS) recorded Depreciation & Amortization (CF) of $2,019 in Q3 2023, down 95.5% from $44,977 a year earlier.

Analysis

Intensity Therapeutics (INTS) Depreciation & Amortization (CF) (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 1.96 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 194.00 Mn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 1.93 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 98.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 56.50 Mn
10 Intensity Therapeutics 10.75 Mn 10.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 2,019.00
Sep 30, 2022 44,977.00
API Access

Intensity Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=INTS&period=max&api_key=YOUR_API_KEY